Skip to main content

Bays F Barry's Form 4 filing

Treace Medical Concepts, Inc. (TMCI) · filed Jan 26, 2023

Accession no.
0001209191-23-005131
Filed
Jan 26, 2023
Trade date
Jan 24-25, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $1.38M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bays F BarryCIK 0001183554Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 24, 2023Common StockSSaleDisposed−25,921$26.03F2−$674,723.631,365,336Direct
Jan 25, 2023Common StockSSaleDisposed−20,467$25.28F3−$517,405.761,344,869Direct
Jan 25, 2023Common StockSSaleDisposed−7,255$25.73F4−$186,671.151,337,614Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.7700 to $26.3700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.6600 to $25.6500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.6600 to $25.8100 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)